Results 51 to 60 of about 11,769,643 (158)

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study

Frontiers in Psychiatry, 2021
Background: One of the main public health strategies adopted at the beginning of the COVID-19 pandemic consisted of implementing strict lockdowns to stop the transmission of the virus.
Dóra Révész, Genís Ona, Genís Ona, Giordano N. Rossi, Juliana M. Rocha, Rafael G. dos Santos, Rafael G. dos Santos, Rafael G. dos Santos, Jaime E. C. Hallak, Jaime E. C. Hallak, Miguel Á. Alcázar-Córcoles, José C. Bouso, José C. Bouso, José C. Bouso   +13 more
doaj   +1 more source

Psychological change processes in alcohol use disorder: A qualitative study of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) with cognitive behavioural therapy

Addiction, EarlyView.
Abstract Background and aims This study qualitatively explored psychological change processes as described by participants and therapists within a phase 2a clinical trial evaluating the safety, tolerability, and preliminary efficacy of a single dose of intranasal 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT; BPL‐003) administered alongside psychological
Mathieu Seynaeve, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, James J. Rucker, Anthony Cleare, John Marsden   +6 more
wiley   +1 more source

The natural hallucinogen 5-MeO-DMT, component of Ayahuasca, disrupts cortical function in rats: reversal by antipsychotic drugs [PDF]

, 2015
5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) is a natural hallucinogen component of Ayahuasca, an Amazonian beverage traditionally used for ritual, religious and healing purposes that is being increasingly used for recreational purposes in US and Europe.
Riga, Maurizio, Artigas, Francesc, Riga, Maurizio S., Tudela, Raúl, Artigas Pérez, Francesc, Soria, Guadalupe, Tudela Fernández, Raúl, Celada, Pau, Celada Pedrosa, Paz   +8 more
core   +1 more source

Understanding Consumption of Illicit Drugs and New Psychoactive Substances in Australia by Triangulating Drug Checking and Wastewater‐Based Epidemiology

Drug Testing and Analysis, Volume 18, Issue 10, Page 1244-1255, October 2026.
First Australian study combining wastewater‐based epidemiology and drug checking, demonstrating how complementary data sources enhance monitoring of illicit drugs and emerging psychoactive substances during high‐use periods. ABSTRACT Consumption of psychotropic drugs is a major economic and public health challenge in Australia.
Muhammad Usman, Malcolm McLeod, Dhayaalini Nadarajan, Joseph Clokey, Pritesh Prasad, Rory Verhagen, Benjamin Tscharke, Maurizio Quinto, Richard Bade   +8 more
wiley   +1 more source

Psychedelics in Mental Health: Opportunities and Challenges

Brain and Behavior, Volume 16, Issue 7, July 2026.
ABSTRACT Psychedelic and substance‐assisted therapies are attracting renewed scientific, clinical, and public interest as potential interventions for mental health disorders, particularly treatment‐resistant depression, post‐traumatic stress disorder, and substance use disorders.
Lena K. L. Oestreich, Nathalie M. Rieser
wiley   +1 more source

Diet and chemical defenses of the Sonoran Desert toad.

PLoS ONE
The Sonoran Desert toad (Incilius alvarius) is the only animal known to secrete the psychedelic compound 5-MeO-DMT as a chemical defense, but the source of 5-MeO-DMT in I. alvarius remains unknown.
Marina D Luccioni, Jules T Wyman, Edgard O Espinoza, Lauren A O'Connell   +3 more
doaj   +1 more source

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 94-108, July 2026.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, Volume 183, Issue 14, Page 3935-3949, July 2026.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells.

PLoS ONE, 2014
The orphan receptor sigma-1 (sigmar-1) is a transmembrane chaperone protein expressed in both the central nervous system and in immune cells. It has been shown to regulate neuronal differentiation and cell survival, and mediates anti-inflammatory ...
Attila Szabo, Attila Kovacs, Ede Frecska, Eva Rajnavolgyi   +3 more
doaj   +1 more source